NSBCC education &training programs are designed to bring cancer researchers together with physical scientists and technologists in order to expedite the develoment of new and effective tools for fighting cancer. Our goal is to have student and postdoctoral researchers who understand the cancer biology or clinical oncology problem, can participate in technology invention, development, and validation, and then can demonstrate the value of the technology in pre-clinical settings and hopefully via participation in human studies. We describe one-on-one mentorship programs within our individual projects designed to bothfacilitate such training, but also catalyze the collaboratory effort. We also describe three NSBCC short courses, taught at each of the participating institutions, that are designed to teach our researchers key fundamental aspects associated with NSBCC-developed technologies, as well as NSBCC ongoing projects. These courses, designed for non-specialists, are complemented with in depth courses designed for more specialist students that are offered at the participating institutions. We also describe internal educational activities that include student and postdoc participation in our annual retreat, biweekly NSBCC Project meetings, site reviews and national CCNE meetings. Mechanisms to facilitate intra- and inter-CCNE collaborations. The educational programs are overseen by our Internal Review Council and annually reviewed by our External Advisory Board. Outreach programs to the local oncology community are enabled via our IMED Core, and additional outreach programs to underrepresented minority students and industry are described. Finally, we describe our outreach to the global community via public data base sharing, publication, and public communication forums.
NSBCC education &training programs are designed to cultivate a new class of scientists that are capable of translating between technology innovation and clinical application. Our outreach programs tiered to maximize the impact with the local oncology community, and the international community of the commercial, clinical, and scientific world.
|Hong, Candice Sun; Graham, Nicholas A; Gu, Wen et al. (2016) MCT1 Modulates Cancer Cell Pyruvate Export and Growth of Tumors that Co-express MCT1 and MCT4. Cell Rep 14:1590-601|
|Poovathingal, Suresh Kumar; Kravchenko-Balasha, Nataly; Shin, Young Shik et al. (2016) Critical Points in Tumorigenesis: A Carcinogen-Initiated Phase Transition Analyzed via Single-Cell Proteomics. Small 12:1425-31|
|Henning, Ryan K; Varghese, Joseph O; Das, Samir et al. (2016) Degradation of Akt using protein-catalyzed capture agents. J Pept Sci 22:196-200|
|Clark, Andrew J; Wiley, Devin T; Zuckerman, Jonathan E et al. (2016) CRLX101 nanoparticles localize in human tumors and not in adjacent, nonneoplastic tissue after intravenous dosing. Proc Natl Acad Sci U S A 113:3850-4|
|Ghosh, Dhiman; Ulasov, Ilya V; Chen, LiPing et al. (2016) TGFÎ²-Responsive HMOX1 Expression Is Associated with Stemness and Invasion in Glioblastoma Multiforme. Stem Cells 34:2276-89|
|Wei, Wei; Shin, Young Shik; Xue, Min et al. (2016) Single-Cell Phosphoproteomics Resolves Adaptive Signaling Dynamics and Informs Targeted Combination Therapy in Glioblastoma. Cancer Cell 29:563-73|
|Shin, Daniel Sanghoon; Ribas, Antoni (2015) The evolution of checkpoint blockade as a cancer therapy: what's here, what's next? Curr Opin Immunol 33:23-35|
|Pan, Dorothy W; Davis, Mark E (2015) Cationic Mucic Acid Polymer-Based siRNA Delivery Systems. Bioconjug Chem 26:1791-803|
|Xue, Min; Wei, Wei; Su, Yapeng et al. (2015) Chemical methods for the simultaneous quantitation of metabolites and proteins from single cells. J Am Chem Soc 137:4066-9|
|Tanaka, Kazuhiro; Sasayama, Takashi; Irino, Yasuhiro et al. (2015) Compensatory glutamine metabolism promotes glioblastoma resistance to mTOR inhibitor treatment. J Clin Invest 125:1591-602|
Showing the most recent 10 out of 50 publications